David A. Foster to Transforming Growth Factor beta
This is a "connection" page, showing publications David A. Foster has written about Transforming Growth Factor beta.
Connection Strength
2.281
-
Chakraborty S, Utter MB, Frias MA, Foster DA. Cancer cells with defective RB and CDKN2A are resistant to the apoptotic effects of rapamycin. Cancer Lett. 2021 12 01; 522:164-170.
Score: 0.736
-
Chatterjee A, Mukhopadhyay S, Tung K, Patel D, Foster DA. Rapamycin-induced G1 cell cycle arrest employs both TGF-? and Rb pathways. Cancer Lett. 2015 May 01; 360(2):134-40.
Score: 0.465
-
Yellen P, Chatterjee A, Preda A, Foster DA. Inhibition of S6 kinase suppresses the apoptotic effect of eIF4E ablation by inducing TGF-?-dependent G1 cell cycle arrest. Cancer Lett. 2013 Jun 10; 333(2):239-43.
Score: 0.404
-
Foster DA, Gadir N. [Can defective TGF-Beta signaling be an Achilles heel in human cancer?]. Ai Zheng. 2008 Aug; 27(8):882-4.
Score: 0.296
-
Gadir N, Lee E, Garcia A, Toschi A, Foster DA. Suppression of TGF-beta signaling by phospholipase D. Cell Cycle. 2007 Nov 15; 6(22):2840-5.
Score: 0.277
-
Le Gendre O, Sookdeo A, Duliepre SA, Utter M, Frias M, Foster DA. Suppression of AKT phosphorylation restores rapamycin-based synthetic lethality in SMAD4-defective pancreatic cancer cells. Mol Cancer Res. 2013 May; 11(5):474-81.
Score: 0.102